{"id":4455,"date":"2025-09-09T13:40:50","date_gmt":"2025-09-09T10:40:50","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4455"},"modified":"2025-09-09T13:43:30","modified_gmt":"2025-09-09T10:43:30","slug":"solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/","title":{"rendered":"Solid Biosciences inicia ensaio cl\u00ednico de fase 3 da terapia gen\u00e9tica SGT-003 (IMPACT DUCHENNE) em homens ambulantes"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>O estudo de fase 3 (NCT07160634) da terapia gen\u00e9tica SGT-003 desenvolvida pela Solid Biosciences est\u00e1 previsto para come\u00e7ar em outubro de 2025 e ser conclu\u00eddo em janeiro de 2029.<\/strong> O estudo SGT-003 Fase 3 incluir\u00e1 80 homens ambulantes; al\u00e9m disso, os locais do estudo ainda n\u00e3o foram compartilhados. <strong>Ler mais<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/pt\/faq-solid-biosciences-sgt-003-gene-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Perguntas frequentes sobre a terapia gen\u00e9tica Solid Biosciences SGT-003<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Estudo de Fase 3 da Terapia G\u00eanica SGT-003 \u2013 NCT07160634 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Este \u00e9 um estudo de Fase 3, duplo-cego, controlado por placebo, cujo objetivo principal \u00e9 avaliar a efic\u00e1cia de uma \u00fanica infus\u00e3o intravenosa de SGT-003 em participantes pedi\u00e1tricos ambulantes do sexo masculino com DMD. Os objetivos secund\u00e1rios incluem a avalia\u00e7\u00e3o de desfechos adicionais de efic\u00e1cia e seguran\u00e7a.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In\u00edcio do estudo (estimado)<\/strong>: 2025-10<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclus\u00e3o prim\u00e1ria (estimada)<\/strong>: 2029-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclus\u00e3o do estudo (estimada)<\/strong>: 2034-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de participantes (estimado)<\/strong>: 80<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tipo de estudo<\/strong>: Intervencionista<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Locais<\/strong>: Ainda n\u00e3o h\u00e1 dados de localiza\u00e7\u00e3o.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Idades eleg\u00edveis para estudo<\/strong>: 7 anos a 11 anos (homens ambulantes)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principais crit\u00e9rios de inclus\u00e3o e exclus\u00e3o. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07160634\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07160634<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Como participar do ensaio cl\u00ednico SGT-003<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Para participar do ensaio cl\u00ednico de fase 3 do SGT-003, voc\u00ea pode usar as informa\u00e7\u00f5es de contato abaixo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nome<\/strong>: Solid Biosciences<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00famero de telefone<\/strong>: 6173374680<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-mail<\/strong>: clinicaltrials@solidbio.com<\/p>","protected":false},"excerpt":{"rendered":"<p>The phase 3 study (NCT07160634) of the SGT-003 gene therapy developed by Solid Biosciences is expected to begin in October 2025 and be completed in January 2029. The SGT-003 Phase 3 study will include 80 ambulant males, moreover the study locations have not yet been shared. Read More: Frequently Asked Questions About Solid Biosciences SGT-003 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4459,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,61,419,110,170,109],"class_list":["post-4455","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-gene-therapy","tag-impact-duchenne","tag-sgt-003","tag-sgt-003-gene-therapy","tag-solid-biosciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=4455"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/4459"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=4455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=4455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=4455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}